Editorial comment on: Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study.
Van Poppel
Hein
H
University Hospital KU Leuven, Belgium. Hendrik.VanPoppel@uzleuven.be
D000726:Androgen Antagonists / Q000008:administration & dosage / Q000009:adverse effects*; D000813:Anilides / Q000008:administration & dosage / Q000009:adverse effects*; D004305:Dose-Response Relationship, Drug; D004965:Estrogen Antagonists / Q000008:administration & dosage*; D005500:Follow-Up Studies; D006177:Gynecomastia / Q000139:chemically induced / Q000517:prevention & control*; D006801:Humans; D008297:Male; D009570:Nitriles / Q000008:administration & dosage / Q000009:adverse effects*; D010146:Pain / Q000139:chemically induced / Q000517:prevention & control*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013629:Tamoxifen / Q000008:administration & dosage*; D014105:Tosyl Compounds / Q000008:administration & dosage / Q000009:adverse effects*; D016896:Treatment Outcome
D000726:Androgen Antagonists; D000813:Anilides; D004965:Estrogen Antagonists; D009570:Nitriles; D014105:Tosyl Compounds; D013629:Tamoxifen; C053541:bicalutamide